Therapeutic formulation for administering tolterodine with controlled release

US6770295B1 · kind B1 · utility

Assignee

• Pharmacia AB · SE

Inventors

• Bo Kreilgard · Hillerød, DK
• Lene Orup Jacobsen · Copenhagen, DK
• Ulla Hoeck · Hillerød, DK
• Helle Kristensen · Tilst, DK
• Torkel Gren · Uppsala, SE
• Lisbeth Nilvebrant · Bromma, SE
• Anders Ringberg · Stockholm, SE
• Martin Wikberg · Lindome, SE
• Bengt Hallén · Sollentuna, SE
• Birgitta Olsson · Stenhamra, SE
• Jan Strömbom · Uppsala, SE

Key dates

• Filing date: Aug 9, 2000
• Grant date: Aug 3, 2004
• Expiry date: Aug 9, 2020

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P13/10
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention is drawn to a method of treating an unstable or overactive urinary bladder by treating the patient with tolterodine or a tolterodine-related compound, or pharmaceutically acceptable salt thereof, with a controlled release formulation that maintains a substantially constant serum level of the active moiety or moieties for at least 24 hours. The present invention is further drawn to a formulation for the method.